Navigation Links
Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020: Transparency Market Research
Date:9/29/2014

ALBANY, New York, September 29, 2014 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Circulating Circulating Tumor Cells (CTCs) Prognostic Technologies Market [Technologies: Tumor Cell Enrichment (Filtration, Centrifugation and Immunological & Immunomagnetic Methods) & Tumor Cell Detection (Molecular Methods and Optical Methods) and Applications: Prostate Cancer, Breast Cancer, Colorectal Cancer and Others] - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020," the global circulating tumor cells (CTCs) prognostic technologies market was valued at USD 0.43 billion in 2013 and is expected to grow at a CAGR of 26.3% from 2014 to 2020, to reach an estimated value of USD 2.16 billion in 2020.

Circulating tumor cells (CTCs) are specialized rare cells that have detached from the primary tumors of the body and disseminated in the vasculature system of the body, eventually causing metastasis. CTCs are composed of particular cells that act as seeds for successive development of additional metastatic tumors in essential distant organs, which is liable for the majority of cancer-related deaths. CTCs are not easily detected since these cells are present in less numbers in the blood stream. Therefore, detection of CTCs during the progression of the tumor provides a prognostic value of the tumor progression as well as evaluates the efficacy of therapeutic intervention.

Browse the full circulating tumor cells (CTCs) prognostic technologies market report: http://www.transparencymarketresearch.com/ctcs-prognostic-technologies-market.html

According to the UICC (Union for International Cancer Control), over the next two decades, globally cancer cases will increase by nearly 75%, reaching almost to 25 million. Additionally, according to the ACS (American Cancer Society), it has been projected that in 2014, approximately 1,665,540 people would be diagnosed with cancer and around 585,720 people would die due to cancer, in the U.S. alone. This escalating base of cancer cases would need next generation prognostic technologies as well as targeted therapeutics for effective diagnosis and treatment of the disease, which would alternatively increase the demand for modern age CTCs prognostic technologies.

The circulating tumor cells (CTCs) prognostic technologies market has been primarily segmented in terms of technology and applications. The technology market further comprises tumor cell enrichment and tumor cell detection. Moreover, the tumor cell enrichment market is further segmented into filtration, centrifugation and immunomagnetic methods; among which, immunomagnetic methods accounted for the largest market due to widespread commercial availability and high effectiveness. Moreover, the CTCs detection market is further bifurcated into molecular methods and optical methods, among which, the optical methods segment is expected to foresee a remarkable growth rate of over 27.3% from 2014 to 2020. Furthermore, the application segment of this market consists of major application areas such as prostate cancer, breast cancer, colorectal cancer and others (lung cancer, ovarian cancer and pancreatic cancer).

A sample of the report in PDF obtained by visiting: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2497

Among the various applications of CTCs prognostic technologies, breast cancer and prostate cancer is expected to witness the fastest growth (27.1% & 25.2% respectively) during the forecast period owing to the high incidence and prevalence rate of these cancers and high adoption rate for CTCs technologies for therapeutic monitoring. However, it is also expected that colorectal cancer as well as other types of cancer will account for an admirable share of the market (24.2 % and 15% respectively in 2013) due to their rising prevalence rate and increasing research and development activities for discovering targeted therapeutics. It is expected that by the year 2020, the market value of CTCs prognostic technologies for application in prostate shall be worth more than USD 684.0 million.

In terms of geography, North America accounted for the largest CTCs prognostic technologies market in the year 2013 (over 50%) followed by Europe. However, Asia Pacific is estimated to exhibit the fastest growth rate owing to the expected rise in various types of cancer coupled with high research and development initiatives and growing adoption rate for advanced prognostic technologies.

Related and Recently Published Reports by Transparency Market Research 


This market is highly consolidated in nature characterized by few players occupying approximately 70% of the overall market share. The major players of this market include Epic Sciences, Inc., Fluxion Biosciences, Inc., Silicon Biosystems, S.p.A., Rarecells USA, Inc. and Veridex, LLC.

The global circulating tumor cells (CTCs) prognostic technologies market is segmented as follows:

Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Technology 

  • Tumor Cell Enrichment
  • Filtration
  • Centrifugation
  • Immunological & Immunomagnetic Methods
  • Tumor Cell Detection
  • Molecular Methods
  • Optical Methods

Press Release of Circulating Tumor Cells (CTCs) Prognostic Technologies Market: http://www.transparencymarketresearch.com/pressrelease/ctcs-prognostic-technologies-market.htm

Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Applications 

  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others (Lung, Ovarian and Pancreatic Cancer)

Circulating Tumor Cells (CTCs) Prognostic Technologies Market, by Geography 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

 About Us: 

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact: 

Sheela AK

State Tower, 90 State Street,

Suite 700, Albany NY - 12207

USA/Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Web: http://www.transparencymarketresearch.com/

Blog: http://www.tmrblog.com/

Blog: http://www.culrav.org/

Blog: http://www.europlat.org/



'/>"/>
SOURCE Transparency Market Research Pvt. Ltd
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Determines MiMedx Allograft Effectively Recruits Circulating Stem and Progenitor Cells
2. Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
3. Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. I maggiori operatori sanitari si riuniscono a ESMO 2014 a sostegno di una cura multidisciplinare per i pazienti europei affetti da tumori di testa e collo
6. Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors
7. GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids
8. Caris Life Sciences Receives Tumor Profiling Industrys First ISO 15189 Medical Laboratory Accreditation
9. Berg lanceert eerste gelaagde geneeskundige klinische proef ten behoeve van onderzoek naar het metabolisme van vaste tumoren
10. Berg startet bisher erste klinische Stratified-Medicine-Studie zur Untersuchung des Krebsstoffwechsels solider Tumoren
11. Berg lancia il primo trial clinico stratificato per eseguire indagini sul metabolismo del cancro nei tumori solidi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2019)... , ... June 18, 2019 , ... ... in Los Angeles County. The office is located at 50 Bellefontaine Street, Suite ... equipment plus all of the top-notch care already offered in all of their ...
(Date:6/18/2019)... ... 2019 , ... The dentists of DiBartola Dental are providing ... area. Understanding the crippling effects patients experience when it comes to dental anxiety, ... same-day oral sedation, nitrous oxide, and IV sedation at their practice. By combining ...
(Date:6/16/2019)... ... June 15, 2019 , ... Dr. Brian ... state-of-the-art treatment with cutting-edge technology, has opened. , The clinic is offering ... capabilities of regenerative medicine. , “Using the remarkable cutting-edge technology of stem ...
Breaking Medicine Technology:
(Date:6/20/2019)... (PRWEB) , ... June 20, 2019 , ... ... to announce their partnership with Physical Therapy Solutions in Lawton, which has joined ... the clinic is the group’s 28th clinic in the state. , Physical ...
(Date:6/19/2019)... ... June 19, 2019 , ... The Clean ... in 2018 by the Alliance and its partners. Under the theme “Investment. Innovation. ... across the clean cooking sector, including an entrepreneur and manufacturer in Africa, a ...
(Date:6/19/2019)... ... 2019 , ... Ovation® Fertility scientists have been invited to present four pieces ... Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s oral presentation about the ... Basic Science Award for Oral Presentation and the Fertility Society of Australia Exchange Award., ...
(Date:6/18/2019)... ... June 18, 2019 , ... ... today announced Steve Einig has joined the organization in the newly created role ... initiatives around market engagement, marketing, strategic events and brand management. , “Steve brings ...
(Date:6/14/2019)... ... June 14, 2019 , ... United Breast Cancer ... scheduled for Saturday, July 13th. UBCF is thrilled to return to the “City ... breast cancer. This second event was added after an overwhelming response to the ...
Breaking Medicine News(10 mins):